answer text |
<p>We understand that a draft clinical commissioning policy to cover the use of ataluren
(Translarna) for the treatment of Duchenne muscular dystrophy is currently going through
NHS England's standard development and decision making processes.</p><p> </p><p> </p><p>
</p><p>NHS England has advised that a meeting of its Clinical Priorities Advisory
Group has been delayed whilst further work is undertaken to refine the overall decision
making process. NHS England remains committed however, to ensuring that a timely decision
is made about a range of investment proposals that have been put forward for the 2015-16
financial year.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England continues
to keep the range of services and treatments available to patients under review as
new evidence and expert guidance becomes available.</p><p> </p><p> </p><p> </p><p>On
9 December 2014, I met with the hon. Member for Leeds North West (Greg Mulholland),
representatives from the Society for Mucopolysaccharide Diseases and Muscular Dystrophy
Campaign, as well as the parents of three children who suffer with Morquio syndrome
and Duchenne muscular dystrophy, to hear their concerns about the continued provision
of innovative drugs for these conditions which have been greatly benefiting their
children.</p><p> </p><p><strong> </strong></p><p> </p>
|
|